Best Stocks To Buy For 2013: Promising

[ April 21, 2014 | Author: Admin | Views: 72776 | Weather: | Mood: normal]

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis. What: Shares of Solazyme (NASDAQ: SZYM  ) fell as much as 20% today after it agreed to dissolve a promising joint venture. So what: Solazyme and Roquette, a starch and starch-derivatives company, agreed to dissolve a joint venture formed in 2010 to create alternative foods from microalgae. The companies couldn’t decide on a manufacturing and marketing strategy so they decided to go their separate ways. Now what: Instead of going forward with Roquette, Solazyme said it will accelerate commercialization of its own food ingredients, so this could result in earlier revenue than the joint venture would’ve provided. But, without the backing of a major food player, the company faces more risks. Until Solazyme can prove that it can … Continue reading

[ April 14, 2014 | Author: Admin | Views: 77640 | Weather: | Mood: normal]

Up until now, crowdfunding has just been a way for consumers to give money to inventors concocting newfangled things ranging from Big Wheel bikes for grown-up and smartphones. But soon, it could become a way to actually invest in those companies. The Securities and Exchange Commission voted unanimously to propose rules that, for the first time, would allow investors to buy stock in companies over the Internet using a crowdfunding exchange. These rules could reinvent the way that companies raise money by allowing them to bypass the traditional costs of going public, which usually involved hiring costly investment bankers and accountants. The SEC’s vote on so-called equity crowdfunding is in direct response to Title III of the JOBS Act, passed last year, in which Congress is looking for a loophole to allow smaller companies to get an exemption from the strict rules controlling the sale of securities to individuals. Congress … Continue reading

[ April 13, 2014 | Author: Admin | Views: 73467 | Weather: | Mood: normal]

Pfizer (NYSE: PFE  ) investors have cheered the stock’s remarkable gains this year, but the company’s performance in the shadow of major patent expirations has been remarkable. New drugs have risen to supplant the firm’s old blockbusters, and rheumatoid arthritis drug Xeljanz, approved by the Food and Drug Administration last year, has led the charge as one of tomorrow’s most promising therapies. Unfortunately, European regulators didn’t feel the same way. Late last week, Europe’s Committee for Medicinal Products for Human Use, or CHMP, recommended that Xeljanz not be approved to treat rheumatoid arthritis across the Atlantic. Should you be worried about Xeljanz’s failure in Europe? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso tell you what you need to know in the video below. Pfizer missed a chance to capture of Europe’s rheumatoid arthritis market with Xeljanz, but it’s still looking up to the biggest immunology drug on … Continue reading

[ April 3, 2014 | Author: Admin | Views: 85953 | Weather: | Mood: normal]

Over the past couple weeks Capstone Turbine (NASDAQ: CPST  ) shares have launched into orbit on the news that the company had secured several orders for its microturbines. But 40% in a month? On the surface, it seems a bit silly that a company could gain that much on a couple news stories about sales. For a company like Capstone, which has struggled with sales, this kind of news is exactly what shareholders were looking for. Capstone has some big advantages in the energy generation space, but it also has some very clear weaknesses. With sales numbers picking up, it could be a sign that the company is tackling one of those weaknesses. In this video, contributor Tyler Crowe explains how these stories might be a promising sign for shareholders, but there are still some major issues that need to be addressed before Capstone makes its way to profitability. For … Continue reading

[ March 24, 2014 | Author: Admin | Views: 14632 | Weather: | Mood: normal]

First Titan Corp. (FTTN) Last Friday, FTTN had shed (-1.02%) down -0.005 at $.435 with 6,500 shares in play at the close (ref. google finance July 19, 2013 Close), but dont let this get you down. First Titan Corp. added to its growing portfolio of Texas oil and gas assets by acquiring a working interest in a promising production package in Waller County, the company previously reported. Known as the Minns asset package, the Waller County project includes a multi-well production package located in the Brookshire Field. The acquisition represents another substantial addition to the companys swelling asset base in the Lone Star State. Texas oil production is in the midst of a major boom, outpacing growth in even North Dakota with output jumping by a third in just 12 months. In addition to FTTNs assets in Waller and Terrell Counties, the company is also in negotiations to acquire a … Continue reading